T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.47B |
| 2 |
NXP Semiconductors
NXPI
|
+$1.73B |
| 3 |
Tesla
TSLA
|
+$1.7B |
| 4 |
Northrop Grumman
NOC
|
+$1.67B |
| 5 |
Dollar Tree
DLTR
|
+$1.6B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$3.29B |
| 2 |
Meta Platforms (Facebook)
META
|
+$1.85B |
| 3 |
Texas Instruments
TXN
|
+$1.82B |
| 4 |
Microsoft
MSFT
|
+$1.27B |
| 5 |
Booking.com
BKNG
|
+$1.18B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.1% |
| 2 | Technology | 17.78% |
| 3 | Consumer Discretionary | 15.32% |
| 4 | Financials | 14.61% |
| 5 | Industrials | 9.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1426
RB Global
RBA
$16B
| $6.5M | ﹤0.01% |
180,000
| – | – |
|
|
ACOR
1427
DELISTED
Acorda Therapeutics
ACOR
| $6.5M | ﹤0.01% |
2,756
+27
| +1% | +$83.6K |
|
1428
Heritage Insurance Holdings
HRTG
$980M
| $6.42M | ﹤0.01% |
433,176
+11,509
| +3% | +$182K |
|
1429
Berkshire Hathaway Class A
BRK.A
$1.09T
| $6.4M | ﹤0.01% |
20
| – | – |
|
|
P
1430
DELISTED
Pandora Media Inc
P
| $6.28M | ﹤0.01% |
660,194
+7,885
| +1% | +$66.4K |
|
1431
Prothena Corp
PRTA
$466M
| $6.09M | ﹤0.01% |
465,273
-332,981
| -42% | -$4.81M |
|
|
MRUS
1432
DELISTED
Merus
MRUS
| $6.04M | ﹤0.01% |
306,216
-40,478
| -12% | -$859K |
|
|
YARW
1433
Yarrow Bioscience, Inc. Common Stock
YARW
$114M
| $5.9M | ﹤0.01% |
+166
| New | +$5.12M |
|
|
PACW
1434
DELISTED
PacWest Bancorp
PACW
| $5.74M | ﹤0.01% |
120,452
-33,337
| -22% | -$1.68M |
|
1435
Jack in the Box
JACK
$358M
| $5.53M | ﹤0.01% |
65,910
-212,734
| -76% | -$18.4M |
|
|
LHO
1436
DELISTED
LaSalle Hotel Properties
LHO
| $5.48M | ﹤0.01% |
158,516
+260
| +0.2% | +$9K |
|
|
IRCP
1437
DELISTED
IRSA Propiedades Comerciales S.A.
IRCP
| $5.48M | ﹤0.01% |
985,448
-223,512
| -18% | -$1.5M |
|
|
PATI
1438
DELISTED
Patriot Transportation Holding, Inc. Common Stock
PATI
| $5.46M | ﹤0.01% |
285,503
-4,600
| -2% | -$95.6K |
|
1439
Arcus Biosciences
RCUS
$3.67B
| $5.41M | ﹤0.01% |
388,390
-255,700
| -40% | -$3.26M |
|
|
JMP
1440
DELISTED
JMP Group LLC
JMP
| $5.38M | ﹤0.01% |
1,014,112
| – | – |
|
|
CLVS
1441
DELISTED
Clovis Oncology, Inc.
CLVS
| $5.32M | ﹤0.01% |
181,088
-135,744
| -43% | -$5.26M |
|
|
WPRT
1442
Westport Fuel Systems
WPRT
$34.6M
| $5.28M | ﹤0.01% |
176,086
-4,120
| -2% | -$117K |
|
1443
United Therapeutics
UTHR
$21.9B
| $5.21M | ﹤0.01% |
40,716
-2,704
| -6% | -$334K |
|
|
WRD
1444
DELISTED
WildHorse Resource Development
WRD
| $5.19M | ﹤0.01% |
219,458
+166
| +0.1% | +$3.56K |
|
1445
UGI
UGI
$7.53B
| $5.12M | ﹤0.01% |
92,239
+1,620
| +2% | +$87.3K |
|
1446
Louisiana-Pacific
LPX
$5.15B
| $5.01M | ﹤0.01% |
188,970
+11,365
| +6% | +$324K |
|
|
PE
1447
DELISTED
PARSLEY ENERGY INC
PE
| $5M | ﹤0.01% |
170,942
+7,143
| +4% | +$212K |
|
1448
ADT
ADT
$5.46B
| $4.96M | ﹤0.01% |
528,558
-11,877,473
| -96% | -$106M |
|
1449
Domo
DOMO
$184M
| $4.93M | ﹤0.01% |
242,029
+90
| +0% | +$1.78K |
|
|
FDC
1450
DELISTED
First Data Corporation
FDC
| $4.92M | ﹤0.01% |
201,194
+26,464
| +15% | +$638K |
|
Similar funds
T. Rowe Price Associates's Q3 2018 Portfolio in Review
As of Q3 2018, T. Rowe Price Associates held 2,658 positions worth $685B, up 4.7% from $654B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
T. Rowe Price Associates's Q3 2018 filing shows 77 new, 1,268 increased, 1,098 reduced and 77 closed positions. Its largest new stake was Fortive Corporation 5.00% Mandatory Convertible Preferred Stock, Series A: 194,161 shares worth $208M. The largest sale was Broadcom, an estimated $3.29B.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 16% a quarter earlier, followed by Technology and Consumer Discretionary.
- T. Rowe Price Associates's largest Q3 2018 buy was Fortive Corporation 5.00% Mandatory Convertible Preferred Stock, Series A: 194,161 shares worth $208M.
- T. Rowe Price Associates added most to NVIDIA in Q3 2018, an estimated $2.47B increase.
- T. Rowe Price Associates's biggest Q3 2018 reduction was Broadcom, cutting an estimated $3.29B.
- T. Rowe Price Associates fully exited DCT Industrial Trust Inc. in Q3 2018, selling an estimated $345M.
- T. Rowe Price Associates's ten largest holdings make up 20% of its $685B portfolio in Q3 2018.
- T. Rowe Price Associates opened 77 new positions and closed 77 in Q3 2018.
- T. Rowe Price Associates's portfolio value rose 4.7% quarter-over-quarter to $685B.
Based on T. Rowe Price Associates's 13F filing for Q3 2018, filed 14 Nov 2018.